Global /South Korea /Healthcare /Drug Manufacturers - General /003220
chevron_leftBack
Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.

003220
KRX: 003220 Delayed
10,720KRW -0.8%
7.02 USD
As of 13 June 2026, Daewon Pharmaceutical Co., Ltd. has a market cap of $152.35M USD, ranking #22791 globally and #981 in South Korea. It ranks #2044 in the Healthcare sector, and #735 in the Drug Manufacturers - General industry.
Global Rank
22791
Country Rank
981
Sector Rank
2044
Industry Rank
735
Key Stats
Market Cap
$152.35MUSD
231.7B KRW
Enterprise Value
$239.75MUSD
365.91B KRW
Revenue (TTM)
$398.1MUSD
605.43B KRW
EBITDA (TTM)
$17.84MUSD
27.23B KRW
Net Income (TTM)
-$907.2KUSD
-1.38B KRW
EBITDA Margin
4.5%
Profit Margin
-0.2%
Forward PE
16.2
PS Ratio
0.4
PB Ratio
0.8
EV/EBITDA
13.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Seung-Ryel Baek open_in_new
Employees
1,283
Founded
1958
Website
daewonpharm.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.8% 1.5% 2.8% -6.9% -18% -21%

News

Loading...

Markets

Exchange Ticker Price
Korea Exchange
MIC: XKRX
PRIMARY
003220
대원제약(주)
ISIN: KR7003220001
Shares Out.:
21.433M1 Shares Float: 12.386M2
TV:
SA:
YF:
GF:
BA:
MS:
10,720 KRW
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Daewon Pharmaceutical Co., Ltd.

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)
Name
Market Cap diff.
PE
$9.15B
13.91T KRW
6K%
-
$6.77B
10.3T KRW
4K%
1958.1
$5.24B
7.97T KRW
3K%
29.9
298380
$4.96B
7.55T KRW
3K%
-
000100
$4.55B
6.92T KRW
3K%
35.9
$4.44B
6.76T KRW
3K%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
500K%
38.1
JNJ
$547.28B
359K%
26.4
ABBV
$360.63B
237K%
97.4
$321.52B
256.25B CHF
211K%
19.9
AZN
$288.84B
215.59B GBP
189K%
27.6
NOVN
$274.65B
218.9B CHF
180K%
20.5
chevron_leftBack